These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34366381)

  • 1. Plasma galectin-9 as a predictor of adverse non-AIDS events in persons with chronic HIV during suppressive antiretroviral therapy.
    Premeaux TA; Moser CB; McKhann A; Hoenigl M; Laws EI; Aquino DL; Lederman MM; Landay AL; Gianella S; Ndhlovu LC;
    AIDS; 2021 Dec; 35(15):2489-2495. PubMed ID: 34366381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.
    Tenorio AR; Zheng Y; Bosch RJ; Krishnan S; Rodriguez B; Hunt PW; Plants J; Seth A; Wilson CC; Deeks SG; Lederman MM; Landay AL
    J Infect Dis; 2014 Oct; 210(8):1248-59. PubMed ID: 24795473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma galectin-9 relates to cognitive performance and inflammation among adolescents with vertically acquired HIV.
    Moar P; Linn K; Premeaux TA; Bowler S; Sardarni UK; Gopalan BP; Shwe EE; San T; Han H; Clements D; Hlaing CS; Kyu EH; Thair C; Mar YY; Nway N; Mannarino J; Bolzenius J; Mar S; Aye AMM; Tandon R; Paul R; Ndhlovu LC
    AIDS; 2024 Aug; 38(10):1460-1467. PubMed ID: 38608008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy.
    Angelidou K; Hunt PW; Landay AL; Wilson CC; Rodriguez B; Deeks SG; Bosch RJ; Lederman MM
    J Infect Dis; 2018 Jun; 218(2):239-248. PubMed ID: 29309629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations Between Plasma Immunomodulatory and Inflammatory Mediators With VACS Index Scores Among Older HIV-Infected Adults on Antiretroviral Therapy.
    Premeaux TA; Javandel S; Hosaka KRJ; Greene M; Therrien N; Allen IE; Corley MJ; Valcour VG; Ndhlovu LC
    Front Immunol; 2020; 11():1321. PubMed ID: 32695109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapy-mediated Viral Suppression.
    Hoenigl M; Moser CB; Funderburg N; Bosch R; Kantor A; Zhang Y; Eugen-Olsen J; Finkelman M; Reiser J; Landay A; Moisi D; Lederman MM; Gianella S;
    Clin Infect Dis; 2019 Aug; 69(4):676-686. PubMed ID: 30418519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals.
    Premeaux TA; D'Antoni ML; Abdel-Mohsen M; Pillai SK; Kallianpur KJ; Nakamoto BK; Agsalda-Garcia M; Shiramizu B; Shikuma CM; Gisslén M; Price RW; Valcour V; Ndhlovu LC
    J Neurovirol; 2019 Apr; 25(2):150-161. PubMed ID: 30478799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galectin-9 is rapidly released during acute HIV-1 infection and remains sustained at high levels despite viral suppression even in elite controllers.
    Tandon R; Chew GM; Byron MM; Borrow P; Niki T; Hirashima M; Barbour JD; Norris PJ; Lanteri MC; Martin JN; Deeks SG; Ndhlovu LC
    AIDS Res Hum Retroviruses; 2014 Jul; 30(7):654-64. PubMed ID: 24786365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring Circulating Immune Checkpoint Proteins as Predictors of Non-AIDS Morbid Events in People With HIV Initiating Antiretroviral Therapy.
    Premeaux TA; Moser CB; McKhann A; Hoenigl M; Yeung ST; Pang APS; Corley MJ; Lederman MM; Landay AL; Gianella S; Ndhlovu LC
    Open Forum Infect Dis; 2022 Mar; 9(3):ofab570. PubMed ID: 35146038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of persistent low-level viremia among HIV patients on antiretroviral therapy: A prospective cohort study.
    Ding H; Xu J; Liu J; Wang Q; Kang J; Li X; Zhang Z; Han X; Jiang Y; Geng W; Shang H
    HIV Med; 2022 Mar; 23 Suppl 1():64-71. PubMed ID: 35293103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiretroviral therapy.
    Masiá M; Padilla S; Álvarez D; López JC; Santos I; Soriano V; Hernández-Quero J; Santos J; Tural C; del Amo J; Gutiérrez F;
    AIDS; 2013 Jan; 27(2):181-9. PubMed ID: 23018442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid decrease of plasma galectin-9 levels in patients with acute HIV infection after therapy.
    Saitoh H; Ashino Y; Chagan-Yasutan H; Niki T; Hirashima M; Hattori T
    Tohoku J Exp Med; 2012 Oct; 228(2):157-61. PubMed ID: 23038209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible role of plasma Galectin-9 levels as a surrogate marker of viremia in HIV infected patients on antiretroviral therapy in resource-limited settings.
    Shete A; Dhayarkar S; Dhamanage A; Kulkarni S; Ghate M; Sangle S; Medhe U; Verma V; Rajan S; Hattori T; Gangakhedkar R
    AIDS Res Ther; 2020 Jul; 17(1):43. PubMed ID: 32678033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4/CD8 ratio normalization rates and low ratio as prognostic marker for non-AIDS defining events among long-term virologically suppressed people living with HIV.
    Han WM; Apornpong T; Kerr SJ; Hiransuthikul A; Gatechompol S; Do T; Ruxrungtham K; Avihingsanon A
    AIDS Res Ther; 2018 Sep; 15(1):13. PubMed ID: 30261902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-9 Mediates HIV Transcription by Inducing TCR-Dependent ERK Signaling.
    Colomb F; Giron LB; Premeaux TA; Mitchell BI; Niki T; Papasavvas E; Montaner LJ; Ndhlovu LC; Abdel-Mohsen M
    Front Immunol; 2019; 10():267. PubMed ID: 30842775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death.
    Boulware DR; Hullsiek KH; Puronen CE; Rupert A; Baker JV; French MA; Bohjanen PR; Novak RM; Neaton JD; Sereti I;
    J Infect Dis; 2011 Jun; 203(11):1637-46. PubMed ID: 21592994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma soluble factor following two decades prolonged suppressive antiretroviral therapy in HIV-1-positive males: A cross-sectional study.
    Sperk M; Zhang W; Nowak P; Neogi U
    Medicine (Baltimore); 2018 Feb; 97(5):e9759. PubMed ID: 29384862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study.
    Ravimohan S; Tamuhla N; Steenhoff AP; Letlhogile R; Nfanyana K; Bellamy SL; MacGregor RR; Gross R; Weissman D; Bisson GP
    Lancet Infect Dis; 2015 Apr; 15(4):429-38. PubMed ID: 25672566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of Oxidative Stress to Non-AIDS Events in HIV-Infected Patients.
    Masiá M; Padilla S; Fernández M; Barber X; Moreno S; Iribarren JA; Portilla J; Peña A; Vidal F; Gutiérrez F;
    J Acquir Immune Defic Syndr; 2017 Jun; 75(2):e36-e44. PubMed ID: 28107228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS.
    Hirsch JD; Gonzales M; Rosenquist A; Miller TA; Gilmer TP; Best BM
    J Manag Care Pharm; 2011 Apr; 17(3):213-23. PubMed ID: 21434698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.